It was estimated that in 2016 in the United Statesapproximately 13% of those with T1DM over the age of 26 years were using an adjuvanttherapy in addition to insulin; 3% were using a SGLT2i and 2.5% a GLP-1RA.15 Most recently, our group published a work showing the real-world benefit ofthese medications in T1DM patients where after 1 year of therapy, GLP-1RA users hadsignificant reductions in weight, hemoglobin A1c (HbA1c), and total daily dose ofinsulin, while SGLT2i users experienced significant reductions in HbA1c and basalinsulin requirements.16 This evidence concerns the gene INS and type 1 diabetes mellitus.